
Aurobindo Pharma

Working at Aurobindo Pharma
Company Summary
Overall Rating

3% above

Highly rated for 
Job security, Salary, Work-life balance
Work Policy




Top Employees Benefits
About Aurobindo Pharma

Founded in 1986 by Mr. P.V. Ramprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born of a vision. The company commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry. Aurobindo Pharma became a public company in 1992 and listed its shares on the Indian stock exchanges in 1995. In addition to being the market leader in Semi-Synthetic Penicillin’s, Aurobindo Pharma has a presence in key therapeutic segments such as neurosciences (CNS), cardiovascular (CVS), anti-retroviral, anti-diabetics, gastroenterology and Anti-biotics Through cost effective manufacturing capabilities and a few loyal customers, the company also entered the high margin specialty generic formulations segment. Today Aurobindo Pharma has evolved into a knowledge driven company manufacturing active pharmaceutical ingredients and formulation products. It is R&D focused and has a multi-product portfolio with manufacturing facilities in several countries.


Apis India

AuroZymes
ABECA - AmbitionBox Employee Choice Awards



Aurobindo Pharma Ratings
Overall Rating





Category Ratings
Job security
Salary
Work-life balance
Work satisfaction
Company culture
Skill development
Promotions
Work Policy at Aurobindo Pharma



Aurobindo Pharma Reviews
Top mentions in Aurobindo Pharma Reviews
Compare Aurobindo Pharma with Similar Companies
![]() | ![]() Change Company | ![]() Change Company | ![]() Change Company | |
---|---|---|---|---|
Overall Rating | 4.0/5 based on 5.1k reviews | 4.0/5 based on 7.3k reviews | 4.1/5 based on 6.5k reviews | 4.1/5 based on 7.4k reviews |
Highly Rated for | Job security Work-life balance Salary | Skill development Company culture Work-life balance | Skill development Company culture Work-life balance | Skill development Salary Work-life balance |
Critically Rated for | ![]() No critically rated category | Promotions | ![]() No critically rated category | ![]() No critically rated category |
Primary Work Policy | Work from office 88% employees reported | Work from office 73% employees reported | Work from office 83% employees reported | Work from office 73% employees reported |
Rating by Women Employees | 3.9 Good rated by 241 women | 3.9 Good rated by 831 women | 4.0 Good rated by 399 women | 4.0 Good rated by 751 women |
Rating by Men Employees | 4.0 Good rated by 4.7k men | 4.0 Good rated by 6.1k men | 4.1 Good rated by 5.8k men | 4.1 Good rated by 6.3k men |
Job security | 4.3 Good | 3.5 Good | 3.7 Good | 3.7 Good |
Aurobindo Pharma Salaries
Technical Assistant

Deputy Manager

Senior Technical Assistant

Research Associate

Executive Production

Scientist

Senior Chemist

Executive Engineer

QA Executive

Executive Assistant

Aurobindo Pharma Interview Questions
Aurobindo Pharma Jobs
Aurobindo Pharma News
Stock Market Today: All You Need To Know Going Into Trade On May 29
- The Nifty 50 closed 73.75 points lower, and the BSE Sensex ended 239.31 points down on the recent trading day.
- Foreign portfolio investors bought stocks worth Rs 4,662.9 crore, while domestic institutional investors were net buyers of equities worth Rs 7,912 crore.
- Upcoming Nifty earnings include companies like Bajaj Auto, Alkem Laboratories, and Amara Raja Energy & Mobility, among others.
- Earnings post-market hours feature companies like Deepak Nitrite, Cummins India, Insecticides (India), and Bata India, with varying financial highlights and performance.
- Stocks in the news include IndusInd Bank, Infosys, Tata Chemicals, DLF, Grasim Industries, LTIMindtree, and Aurobindo Pharma, reflecting various corporate developments.
- Recent IPO offerings like Aegis Vopak Terminals, Schloss Bangalore, Prostarm Info Systems, and Scoda Tubes had varying subscription rates on different days.
- Insider trading activities of companies like Supreme Industries, Asahi India Glass, Usha Martin, and Voltamp Transformers were reported recently.
- Currency update reveals the Indian rupee weakened by 3 paise against the US dollar, closing at 85.37.
- Market observations included Nifty futures down by 0.46%, a decrease in Nifty May futures open interest, and notable open interest levels for Nifty Options May 29 Expiry.
- Trading tweaks, F&O cues, and the latest currency update provide insights into recent market activities and trends for investors and traders.

Aurobindo Pharma Q4 Review: Well-Placed To Capture Market Opportunities, Says Motilal Oswal, Maintaining Buy
- Aurobindo Pharma exhibited slightly better-than-expected sales/Ebitda (2%/3% beat) for the quarter.
- Aurobindo Pharma delivered the highest-ever quarterly Ebitda in Q4 FY25, led by a higher offtake in the US generics segment and steady traction in the EU segment.
- Motilal Oswal reiterates Buy for Aurobindo Pharma's stock due to its attractive valuation of 16x FY26E EPS of Rs 73/14x FY27E EPS of Rs 83.5.

Aurobindo Pharma Share Price Rises After Q4 Revenue Growth
- Aurobindo Pharma's share price rose over 2% after reporting a 10.6% year-on-year increase in consolidated revenue to Rs 8,382 crore in Q4 FY25.
- Despite a slight dip in net profit, the company's overall performance was boosted by revenue growth across its business segments.
- The US formulations segment revenue increased by 13.5% to Rs 4,072 crore, while the Europe formulations segment saw a rise of 17.2% year-on-year to Rs 2,147 crore.
- Analysts maintain a positive outlook on Aurobindo Pharma, with 23 out of 29 analysts tracking the company recommending a 'buy' rating, indicating an average 12-month consensus price target implying a 25.2% upside.

Stock Market Live: GIFT Implies Muted Start; Aurbindo Pharma, KEC International, PTC India Shares In Focus
- Asian markets in Japan and South Korea show a decline as investors wait for trade updates and assess China's April industrial profit growth data.
- The GIFT Nifty was flat at 25,035.00, indicating a neutral start for the Nifty 50 index. Aurbindo Pharma, KEC International, PTC India shares will be in focus due to fourth-quarter earnings.
- Benchmark indices closed higher on Monday with NSE Nifty 50 up by 0.60% at 25,001 and BSE Sensex increased by 0.56% at 82,176 amid domestic market volatility.
- Key resistance areas for traders are predicted at 25,150–25,250/82500-82800, with support zones at 24,870/81900. Bullish sentiment is expected above the support level.

Stock Market Today: All You Need To Know Before Going Into Trade On May 27
- The NSE Nifty 50 closed 148 points, or 0.60% higher at 25,001 and the BSE Sensex ended 455.37 points, or 0.56% up at 82,176.
- Foreign portfolio investors mopped up stocks worth Rs 136 crore, while domestic institutional investors stayed net buyers for the fifth straight day.
- Key earnings to watch include companies like Life Insurance Corporation of India, Bosch, ITI, NMDC, Procter & Gamble Hygiene and Health Care, among others.
- Post-market earnings highlights cover companies like Aurobindo Pharma, Brainbees Solutions, Hi-Tech Pipes, Schneider Electric, Shilpa Medicare, and Sumitomo Chemical.
- Stocks in the news include Garden Reach Shipbuilders & Engineers, InterGlobe Aviation, PG Electroplast, KEI Industries, and Thirumalai Chemicals, among others.
- IPO offerings like Aegis Vopak Terminals and Schloss Bangalore (Leela Hotels IPO) are subscribed partially, while Prostarm Info Systems is set to offer shares for bidding.
- In trading tweaks, price bands change, companies announce dividends, and Nifty May Futures and Options cues are observed along with currency update.
- The Indian rupee strengthened by 12 paise to close at 85.1 against the US dollar on Monday amid various global and domestic economic factors.

Q4 Results Live: Gillette, KEC International, Blue Dart, Nazara Technologies In Focus
- Nearly 30 companies, including Gillette, KEC International, Blue Dart, and Nazara Technologies, are set to report their March-quarter results today.
- Other companies announcing their final quarter results today include Bayer CropScience, RateGain Travel Tech, and Olectra Greentech.
- Aurobindo Pharma is estimated to post a 9.4% increase in revenue, with projected Ebitda at Rs 1,826.5 crore and net profit at Rs 1,013 crore.
- Stay updated with NDTV Profit's live coverage of Q4 earnings for the latest updates on companies like Gillette, KEC International, Blue Dart, and Nazara Technologies.

Stock Market Today: All You Need To Know Before Going Into Trade On May 26
- On Friday, NSE Nifty 50 closed 243.45 points higher, while BSE Sensex ended 769 points up.
- Foreign portfolio investors turned net buyers on Friday, purchasing Indian equities worth Rs 1,794.59 crore.
- Domestic institutional investors remained net buyers for the fourth consecutive day, buying equities worth Rs 299.78 crore.
- Key stocks to watch for earnings include Aurobindo Pharma, Blue Dart Express, and Maharashtra Seamless, among others.
- JSW Steel reported Q4 highlights with increased revenue, Ebitda, net profit, and capacity utilization achievements.
- Several companies announced earnings, including Balkrishna Industries, Glenmark Pharma, Reliance Infrastructure, and more.
- Stocks in the news: Bharti Airtel, TVS Srichakra, Lupin, Sun Pharma, and others shared updates on orders, investments, and developments.
- Bulk deals involved companies like Cartrade Tech, Gravita India, and Interarch Building Solutions, among others.
- IPO offerings from companies such as Belrise Industries, Aegis Vopak Terminals, and Schloss Bangalore were subscribed or set for bidding.
- Trading tweaks included price band changes, ex-dividend declarations, block deals, F&O cues, and a currency update on the Indian rupee.

Aurobindo Pharma, KEC International, Blue Dart Express Q4 Results Today — Earnings Estimates
- Aurobindo Pharma, KEC International, and Blue Dart Express are set to announce their fourth-quarter results today.
- Aurobindo Pharma is estimated to report a 9.4% increase in consolidated revenue at Rs 8,197 crore, with projected Ebitda of Rs 1,013 crore and net profit of Rs 1,013 crore.
- KEC International is estimated to have a revenue of Rs 7,078 crore, projected Ebitda of Rs 554.5 crore, and net profit of Rs 261 crore.
- Blue Dart Express is estimated to report a revenue of Rs 1,450 crore, with projected Ebitda of Rs 234 crore and net profit of Rs 76 crore.

Q4 Results 2025 Next Week: Bajaj Auto, Bharat Dynamics, IRCTC, Nykaa Among 2000+ Companies To Declare Earnings
- Over 2,100 companies, including Bajaj Auto, Bharat Dynamics, IRCTC, and Nykaa, are set to announce their quarterly and full-year results next week for the financial year ending March 2025.
- Key players such as Blue Dart Express, NBCC, Gillette India, Apollo Hospitals Enterprise, AJAX Engineering, and Bosch will release their Q4 and FY25 results.
- Investors and analysts will focus on performance metrics as companies make decisions on financial report approval, dividends, and fundraising during Board meetings.
- The earnings season will include companies like Ayush Wellness and Brainbees Solutions, with the latter being the parent company of online retailer FirstCry.
- Various companies across different sectors, including healthcare, manufacturing, and technology, will disclose their results throughout the week.
- Important dates for Q4FY25 results include May 26 for companies like Gillette India, Global Capital Markets, and Bajaj Healthcare.
- Companies like JK Lakshmi Cement, Univa Foods, and Aurobindo Pharma are also among those announcing their results next week.
- The earnings announcements will lead to potential market impacts as companies may declare dividends based on their performance for the year.
- On May 30, Apollo Hospitals Enterprise Ltd. is scheduled to discuss its audited financial results for FY25, along with dividend declarations and other business matters.
- The upcoming week will be crucial for investors and stakeholders as they track the financial performances and strategic decisions of these prominent companies.

Stock Market Today: All You Need To Know Going Into Trade On May 14
- The NSE Nifty 50 and BSE Sensex closed lower on Tuesday's trading session with Nifty down by 1.39% and Sensex by 1.55%.
- Foreign investors turned net sellers of Indian equities on Tuesday by offloading equities worth Rs 476.9 crore.
- Domestic institutional investors bought equities worth Rs 4,273.8 crore, remaining net buyers for the third session.
- Coromandel International Ltd and Nykaa were added to the MSCI Global Standard Index with potential inflows in millions.
- Key events to watch include the announcement of wholesale inflation data for April on Wednesday.
- Earnings focus includes companies like Eicher Motors, Aditya Birla Real Estate, Apollo Tyres, and more.
- Post-market, companies like Siemens, Tata Motors, GlaxoSmithKline Pharmaceuticals reported their Q2 and Q4 FY25 earnings.
- Multiple companies like PTC India, Avenue Supermarts, and Aurobindo Pharma made significant announcements.
- Stocks in news included Puravankara, Punjab National Bank, IDBI Bank, and Mahindra Lifespace Developers among others.
- Trading tweaks, F&O cues, and currency updates also played a role in the market movement.


Aurobindo Pharma Subsidiaries

Eugia Pharma Specialities

APL Healthcare

Auro Peptides

Silicon Life Sciences

Tergene Biotech

APL RESEARCH CENTRE
Aurobindo Pharma Offices
Compare Aurobindo Pharma with




















Contribute & help others!
Companies Similar to Aurobindo Pharma












Aurobindo Pharma FAQs


Reviews
Interviews
Salaries
Users

